Publication | Closed Access

LO1 : Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: The RUBY-I study

Hcv Gt1 InfectionViral HepatitisMedicineAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyChronic Viral InfectionAntiviral DrugChronic Kidney DiseaseRuby-i StudyEnd-stage Renal DiseaseNephrology